KCNQ4 channel activation by BMS-204352 and retigabine

Activation of potassium channels generally reduces cellular excitability, making potassium channel openers potential drug candidates for the treatment of diseases related to hyperexcitabilty such as epilepsy, neuropathic pain, and neurodegeneration. Two compounds, BMS-204352 and retigabine, presentl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropharmacology 2001-06, Vol.40 (7), p.888-898
Hauptverfasser:	Schrøder, Rikke Louise, Jespersen, Thomas, Christophersen, Palle, Strøbæk, Dorte, Jensen, Bo Skaaning, Olesen, Søren-Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticonvulsants - chemistry Anticonvulsants - pharmacology Anticonvulsants. Antiepileptics. Antiparkinson agents Biological and medical sciences Carbamates - chemistry Carbamates - pharmacology Cell Line Cell membranes. Ionic channels. Membrane pores Cell structures and functions Dose-Response Relationship, Drug Epilepsy Fundamental and applied biological sciences. Psychology Humans Indoles - chemistry Indoles - pharmacology Ischemia KCNQ channels KCNQ Potassium Channels linopirdine M-current Medical sciences Molecular and cellular biology Neuropharmacology Neuroprotective agent Pharmacology. Drug treatments Phenylenediamines - chemistry Phenylenediamines - pharmacology Potassium Channels - drug effects Potassium Channels - physiology Potassium Channels, Voltage-Gated Retigabine Stroke
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!